4 1 f4jmg011603.txt STATEMENT OF CHANGES IN BENEFICIAL OWERSHIP U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ================================================================================ 1. Name and Address of Reporting Person* GREGORY JOHN M. -------------------------------------------------------------------------------- (Last) (First) (Middle) 340 EDGEMONT AVENUE, SUITE 500 -------------------------------------------------------------------------------- (Street) BRISTOL, TN 37620 -------------------------------------------------------------------------------- (City) (State) (Zip) ================================================================================ 2. Issuer Name and Ticker or Trading Symbol CELLEGY PHARMACEUTICALS, INC. (CLGY) ================================================================================ 3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary) ================================================================================ 4. Statement for Month/Day/Year 01/16/2003 ================================================================================ 5. If Amendment, Date of Original (Month/Day/Year) ================================================================================ 6. Relationship of Reporting Person to Issuer (Check all applicable) [ ] Director [ X ] 10% Owner [ ] Officer (give title below) [ ] Other (specify below) ================================================================================ 7. Individual or Joint/Group Filing (Check applicable line) [ ] Form filed by one Reporting Person [ X ] Form filed by more than one Reporting Person ================================================================================ Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned ================================================================================
5. 6. 4. Amount of Owner- Securities Acquired (A) or Securities ship 2A. 3. Disposed of (D) Beneficially Form: 7. Deemed Transaction (Instr. 3, 4 and 5) Owned Follow- Direct Nature of 2. Execution Code ------------------------------- ing Reported (D) or Indirect 1. Transaction Date, if (Instr. 8) (A) Transaction Indirect Beneficial Title of Security Date any ------------ Amount or Price (Instr. 3 (I) Ownership (Instr. 3) (mm/dd/yy) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4) ------------------------------------------------------------------------------------------------------------------------------------ COMMON STOCK 01/16/03 N/A P 202,467 A $5.52 4,850,524 D ------------------------------------------------------------------------------------------------------------------------------------ COMMON STOCK 01/17/03 N/A P 33,806 A $5.44 4,884,330 D ====================================================================================================================================
* If the Form is filed by more than one Reporting Person, see Instruction 4(b)(v). Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Page 1 of 3 FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================
9. Number of 10. Deriv- Owner- ative ship 2. Secur- of Conver- 5. 7. ities Deriv- 11. sion Number of Title and Amount Bene- ative Nature of Derivative 6. of Underlying 8. ficially Secur- of Exer- 3A. 4. Securities Date Securities Price Owned ity: In- cise 3. Deemed Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of Follow- Direct direct Price Trans- Execu- action or Disposed Expiration Date ---------------- Deriv- ing (D) or Bene- 1. of action tion Code of(D) (Month/Day/Year) Amount ative Reported In- ficial Title of Deriv- Date Date, (Instr. (Instr. 3, ---------------- or Secur- Trans- direct Owner- Derivative ative (Month/ (Month/ 8) 4 and 5) Date Expira- Number ity action(s)(I) ship Security Secur- Day/ Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr. (Instr. 3) ity Year) Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4) ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ =============================================================================================================================
Explanation of Responses: By: /s/ John M. Gregory 01/17/2003 ----------------------------------------- ----------------------- **Signature of Reporting Person Date ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedures. Alternatively, this Form is permitted to be submitted to the Commission in electronic format at the option of the reporting person pursuant to Rule 101(b)(4) of Regulation S-T. Page 2 of 3 JOINT FILER INFORMATION Name: Joan P. Gregory Address: 340 Edgemont Avenue, Suite 500 Bristol, TN 37620 Designated Filer: John M. Gregory Issuer & Ticker Symbol: Cellegy Pharmaceuticals, Inc. (CLGY) Date of Event Requiring Statement: January 16, 2003 Signature: /s/ Joan P. Gregory ------------------------------ Page 3 of 3 pages